Efficacy and safety of casirivimab/imdevimab (REGEN-COV) in pregnant individuals with COVID-19: Literature review and insights from the COVID-19 International Drug Pregnancy Registry.

IF 0.8 Q4 OBSTETRICS & GYNECOLOGY

Obstetric Medicine Pub Date : 2025-06-09 DOI:10.1177/1753495X251343113

Diego F Wyszynski, Vincent Yau, Daniel Keebler, Cheryl Renz, Jane Ives, Andrew Fitzgibbon, Lee P Shulman

{"title":"Efficacy and safety of casirivimab/imdevimab (REGEN-COV) in pregnant individuals with COVID-19: Literature review and insights from the COVID-19 International Drug Pregnancy Registry.","authors":"Diego F Wyszynski, Vincent Yau, Daniel Keebler, Cheryl Renz, Jane Ives, Andrew Fitzgibbon, Lee P Shulman","doi":"10.1177/1753495X251343113","DOIUrl":null,"url":null,"abstract":"Introduction: Casirivimab/imdevimab (CAS/IMD) comprises two monoclonal antibodies that neutralize SARS-CoV-2. Pregnant individuals were excluded from initial trials, limiting safety data.Methods: The COVID-19 International Drug Pregnancy Registry enrolled 53 pregnant women treated with CAS/IMD, with 34 live births.Results: No safety concerns were identified.Discussion and conclusions: The findings of the COVID-PR study support the safety of CAS/IMD during pregnancy, adding to the growing body of evidence on COVID-19 treatments for this population. The available literature shows that CAS/IMD is effective in preventing the progression to severe COVID-19 in pregnant individuals. The drugs are well-tolerated, and there is no compelling evidence of adverse maternal or neonatal outcomes. The results from the COVID-PR study are consistent with those of the broader literature.","PeriodicalId":51717,"journal":{"name":"Obstetric Medicine","volume":" ","pages":"1753495X251343113"},"PeriodicalIF":0.8000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149162/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetric Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1753495X251343113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Casirivimab/imdevimab (CAS/IMD) comprises two monoclonal antibodies that neutralize SARS-CoV-2. Pregnant individuals were excluded from initial trials, limiting safety data.

Methods: The COVID-19 International Drug Pregnancy Registry enrolled 53 pregnant women treated with CAS/IMD, with 34 live births.

Results: No safety concerns were identified.

Discussion and conclusions: The findings of the COVID-PR study support the safety of CAS/IMD during pregnancy, adding to the growing body of evidence on COVID-19 treatments for this population. The available literature shows that CAS/IMD is effective in preventing the progression to severe COVID-19 in pregnant individuals. The drugs are well-tolerated, and there is no compelling evidence of adverse maternal or neonatal outcomes. The results from the COVID-PR study are consistent with those of the broader literature.

查看原文本刊更多论文

casirivimab/imdevimab （REGEN-COV）在COVID-19妊娠个体中的有效性和安全性：文献综述和来自COVID-19国际药物妊娠登记处的见解

Casirivimab/imdevimab （CAS/IMD）由两种单克隆抗体组成，可中和SARS-CoV-2。孕妇被排除在初始试验之外，限制了安全性数据。方法：在COVID-19国际药物妊娠登记处登记了53例接受CAS/IMD治疗的孕妇，其中34例活产。结果：未发现安全问题。讨论和结论：COVID-PR研究的结果支持妊娠期间CAS/IMD的安全性，为这一人群的COVID-19治疗提供了越来越多的证据。现有文献表明，CAS/IMD可有效预防孕妇发展为严重的COVID-19。这些药物耐受性良好，没有令人信服的证据表明有不良的孕产妇或新生儿结局。COVID-PR研究的结果与更广泛的文献一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obstetric Medicine OBSTETRICS & GYNECOLOGY-

CiteScore

1.90

自引率

0.00%

发文量